Table 2. Characteristics of articles included in the Meta-analysis.
| First author, year | VA |
Proportion of eyes with a significantly improvementc |
Complications (RON/control) |
||||
| Preoperative (RON/Control) | Outcome (RON/Control) | RON | Control | Retinal detachment | Neovascular glaucoma | Vitreous hemorrhage | |
| Aggermann T, 2012[14]a | 1.46 (0.9-1.36)/1.02 (0.75-2) | 0.75 (0.46-1.22)/0.86 (0.51-1.78) | 18/38 | 2/25 | 1:38/0:25 | 2:38/3:25 | 1:38/0:25 |
| Aggermann T, 2012[14]b | 1.46 (0.9-1.36)/1.02 (0.9-1.36) | 0.75 (0.46-1.22)/1.02 (0.85-3) | 18/38 | 5/20 | 1:38/0:20 | 2:38/3:20 | 1:38/2:20 |
| Crama N, 2010[16] | HM,14,14/17,50,35d | CF,CF,5/62,70,78d | 1/3 | 3/3 | NA | 1:3/0:3 | NA |
| Yamamoto T, 2009[15] | (16/200±20/51)/(10/200±20/69) | (20/182±20/43)/(20/154±20/65) (20/167±20/43)/(20/200±20/111) | 2/11 5/11 | 6/10 5/10 | 1:11/0:10 | 2:11/4:10 | 2:11/1:10 |
| Callizo J, 2009[17] | 0.10±0.087/0.23±0.18 | 0.23±0.20/0.28±0.19 | NA | NA | 1:28/0:35 | 1:28/4:35 | 1:28/3:35 |
| Kim TW, 2005[18] | (1.365±0.78)/(1.104±0.77) | NA | 1/11 1/11 | 0/16 0/16 | NA | 0:11/2:16 | 1:11/0:16 |
NA: Not available; HM: Hand movement; FC: Finger count. aA control group as a single dose of 4 mg IVT; bA control group who received a sham injection (placebo); cProportion of eyes with a significantly improvement defined as an improvement of 3 lines of logMAR scale, a 3-line change on the ETDRS chart, improvement from LP to HM or from HM to FC; dDescribed in ETDRS.
n=5